Details for Patent: 9,079,912
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,079,912 protect, and when does it expire?
Patent 9,079,912 protects OPZELURA and JAKAFI and is included in two NDAs.
Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and fifty-two patent family members in thirty-four countries.
Summary for Patent: 9,079,912
Title: | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Abstract: | The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. |
Inventor(s): | Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE) |
Assignee: | Incyte Corporation (Wilmington, DE) |
Application Number: | 14/274,948 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,079,912 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,079,912
International Family Members for US Patent 9,079,912
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 057995 | See Plans and Pricing | |||
Austria | 525374 | See Plans and Pricing | |||
Australia | 2006326548 | See Plans and Pricing | |||
Brazil | PI0619817 | See Plans and Pricing | |||
Canada | 2632466 | See Plans and Pricing | |||
China | 101448826 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |